What if the most affordable and effective treatment for autoimmune diseases isn’t a pill—but light? In this episode, Adi Soozin interviews John McMahon, the medtech veteran behind over $500 million in exits and now co-founder of Cytoind, a company harnessing narrowband UVB phototherapy to retrain the immune system—safely, affordably, and with stunning early results.Recently featured on the cover of Scientific American, Cytoind’s tech mimics sunlight to reduce MS fatigue and may hold the key to treating other autoimmune diseases. With existing insurance coverage, FDA engagement, and a $4M raise underway for their pivotal trial, this episode dives into one of the most exciting biotech frontiers—and a rare investment opportunity.From the biology of light to billion-dollar potential, this is a must-listen for founders, investors, and futurists alike.